Last updated: November 12, 2026
Daclizumab’s commercial trajectory ended with a rapid global withdrawal. The biologic generated limited revenue as Zinbryta for relapsing multiple sclerosis before safety concerns involving severe liver injury and immune-mediated encephalitis led to discontinuation in 2018. U.S. sales were approximately $21 million in 2016 and $46 million in 2017, according to Biogen’s annual reports. The product no longer has active commercial potential in multiple sclerosis, and generic or biosimilar entry is not the primary competitive issue.
What is daclizumab and how was it commercialized?
Daclizumab is a humanized monoclonal antibody targeting CD25, the alpha subunit of the interleukin-2 receptor. Its development history spans transplantation, oncology research, and multiple sclerosis.
| Item |
Detail |
| Active ingredient |
Daclizumab |
| Mechanism |
CD25-directed monoclonal antibody |
| Original brand |
Zenapax |
| Multiple sclerosis brand |
Zinbryta |
| Developers |
Biogen and AbbVie |
| Primary indication |
Relapsing forms of multiple sclerosis |
| U.S. approval |
May 27, 2016 |
| European authorization |
July 2016 |
| U.S. withdrawal |
May 2018 |
| European withdrawal |
May 2018 |
| Current commercial status |
Withdrawn globally |
Roche originally commercialized Zenapax for prevention of acute organ rejection after kidney transplantation. The FDA approved Zenapax in 1997. Roche discontinued the product in the United States in 2009 for commercial reasons, according to FDA records.
Biogen and AbbVie later developed daclizumab for multiple sclerosis. Biogen held rights to commercialize Zinbryta in several major markets, while AbbVie participated in development and commercialization arrangements.
What were daclizumab’s FDA regulatory milestones?
The FDA approved Zinbryta for adults with relapsing forms of multiple sclerosis who had an inadequate response to two or more therapies. The approval included a boxed warning for serious liver injury and other potentially life-threatening risks.
Daclizumab regulatory timeline
| Date |
Regulatory or commercial event |
| 1997 |
FDA approves Zenapax for kidney-transplant rejection prevention |
| 2009 |
Roche discontinues Zenapax in the U.S. |
| May 27, 2016 |
FDA approves Zinbryta for relapsing multiple sclerosis |
| July 2016 |
European Commission authorizes Zinbryta |
| 2017 |
FDA strengthens warnings after reports of severe liver injury |
| March 2018 |
EMA recommends immediate suspension and withdrawal |
| April 2018 |
Biogen and AbbVie announce global voluntary withdrawal |
| May 2018 |
FDA accepts withdrawal of Zinbryta from the U.S. market |
| 2018 |
European marketing authorization withdrawn |
The FDA approval was narrower than the broad multiple sclerosis market opportunity. Zinbryta was positioned for patients with inadequate responses to other disease-modifying therapies, limiting its addressable market from the start.
Why was daclizumab withdrawn from the market?
Daclizumab was withdrawn because of serious and sometimes fatal immune-mediated adverse events.
Reported safety problems included:
- Severe or fatal liver injury
- Autoimmune hepatitis
- Encephalitis
- Meningoencephalitis
- Cerebral vasculitis
- Other inflammatory or immune-mediated neurological disorders
The EMA reported cases of serious inflammatory brain disorders, including encephalitis and meningoencephalitis. The agency concluded that the risks outweighed the benefits in multiple sclerosis patients.
The U.S. product label already carried a boxed warning for liver injury and required a restricted distribution and monitoring program. Those risk controls did not preserve the product’s commercial viability after additional neurological safety cases emerged.
The withdrawal was voluntary rather than the result of a conventional generic challenge or a patent invalidity ruling. The principal value driver changed from market expansion to safety-risk containment.
How did daclizumab sales develop before withdrawal?
Daclizumab sales were modest relative to leading multiple sclerosis biologics and did not establish a durable revenue base.
| Fiscal year |
Reported Zinbryta revenue |
Commercial interpretation |
| 2016 |
Approximately $21 million |
Partial-year sales after U.S. launch |
| 2017 |
Approximately $46 million |
Full-year sales remained limited |
| 2018 |
No durable commercial trajectory |
Product withdrawn during the year |
Biogen reported Zinbryta revenue of $21 million in 2016 and $46 million in 2017. The product’s sales were small compared with Biogen’s multiple sclerosis portfolio, particularly Tecfidera, Avonex, and Plegridy.
The revenue trajectory reflected four constraints:
- The approved population was treatment-experienced and relatively narrow.
- Physicians had access to established alternatives with broader adoption.
- Liver monitoring created operational friction.
- The boxed warning and subsequent neurological safety reports weakened prescribing confidence.
The withdrawal eliminated future product revenue, reduced the value of remaining commercial infrastructure, and ended the economic rationale for further market development.
How did Zinbryta compare with competing multiple sclerosis drugs?
Daclizumab entered a market dominated by established disease-modifying therapies. Its commercial position was weaker than that of products with longer safety histories, broader labels, oral administration, or entrenched physician use.
| Product |
Company |
Modality |
Market position before Zinbryta withdrawal |
| Tecfidera |
Biogen |
Oral small molecule |
High-volume oral MS therapy |
| Gilenya |
Novartis |
Oral small molecule |
Established relapsing MS treatment |
| Tysabri |
Biogen |
Monoclonal antibody |
High-efficacy therapy with known monitoring risks |
| Lemtrada |
Sanofi |
Monoclonal antibody |
Escalation therapy for active disease |
| Copaxone |
Teva |
Injectable peptide |
Established platform therapy |
| Avonex |
Biogen |
Interferon beta |
Long-standing injectable treatment |
| Plegridy |
Biogen |
Pegylated interferon |
Lower-frequency injectable treatment |
| Zinbryta |
Biogen/AbbVie |
Anti-CD25 antibody |
Restricted, safety-limited entrant |
Zinbryta was administered by subcutaneous injection, generally once monthly. That dosing schedule was commercially attractive, but it did not offset safety monitoring and the product’s restricted positioning.
What patents protected daclizumab and Zinbryta?
Daclizumab’s patent position was less commercially important than its regulatory and safety profile by the time Zinbryta launched.
The relevant intellectual-property categories included:
- Antibody composition patents
- Humanized anti-CD25 antibody claims
- Pharmaceutical composition claims
- Methods of treating multiple sclerosis
- Dosing and administration claims
- Manufacturing and cell-culture processes
The original Zenapax-era composition and antibody patents were generally old by the time of the 2016 multiple sclerosis approval. Later patent protection could have covered therapeutic use, formulations, manufacturing, or specific dosing regimens, but those rights had little practical value after the product was withdrawn.
Did Orange Book patents block generic daclizumab?
Daclizumab was a biologic licensed under the Public Health Service Act, not a conventional small-molecule drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act. As a result, the central regulatory pathway was biosimilar approval under section 351(k), not an ANDA-based generic pathway.
The FDA’s Purple Book, rather than the Orange Book, is the relevant reference for biological products. The commercial question therefore was not whether a generic manufacturer would file a Paragraph IV certification against an Orange Book patent. The more relevant questions would have been whether:
- A biosimilar could be developed;
- Reference-product exclusivity had expired;
- Patent litigation would delay launch; and
- Any remaining market justified development costs.
No commercially meaningful biosimilar program emerged after withdrawal.
When did daclizumab lose exclusivity?
Daclizumab lost practical exclusivity when its market authorization was withdrawn in 2018, not when a patent or regulatory exclusivity period expired.
For the MS indication, the principal commercial end date was May 2018. The product could no longer be supplied as a marketed treatment in the United States or European Union. Any residual patent term therefore became commercially irrelevant to the withdrawn indication.
The FDA’s biologic exclusivity framework also did not create a durable value position. Zinbryta was approved before the modern commercial biosimilar market had developed, but safety failure occurred before biosimilar competition could become material.
Were there Paragraph IV challenges or patent litigation involving daclizumab?
No major Paragraph IV challenge drove the market outcome. Daclizumab’s commercial failure resulted from safety concerns and voluntary withdrawal, not from an ANDA launch or a patent settlement.
The distinction matters:
- No conventional generic-entry event ended the product’s revenue.
- No public patent settlement defined market timing.
- No biosimilar competitor captured the product’s market.
- The principal threat was regulatory withdrawal rather than patent erosion.
Potential disputes involving manufacturing, antibody rights, licensing, or development arrangements would not have changed the central market outcome after the 2018 withdrawal.
What licensing deals affected daclizumab’s commercial value?
Daclizumab was developed through a collaboration involving Biogen and AbbVie. The commercial structure linked Biogen’s multiple sclerosis franchise with AbbVie’s immunology and biologics capabilities.
The economics were affected by:
- Shared development responsibilities;
- Regional commercialization rights;
- Manufacturing obligations;
- Postmarketing safety commitments; and
- The allocation of withdrawal-related costs.
Once Zinbryta was withdrawn, the expected value of future royalties, milestone payments, and commercial profits fell sharply. The collaboration’s remaining value was primarily associated with inventory disposition, safety monitoring, regulatory closure, and intellectual-property management.
What was the financial impact of daclizumab’s withdrawal?
The direct revenue loss was limited because Zinbryta had not reached blockbuster scale. The more important financial effects were indirect.
Revenue exposure
Zinbryta represented a small portion of Biogen’s total revenue. Its withdrawal did not materially threaten Biogen’s overall financial position because the company had a diversified multiple sclerosis portfolio and other pipeline assets.
Cost exposure
Withdrawal generated potential costs related to:
- Patient transition programs;
- Pharmacovigilance;
- Regulatory submissions;
- Product recall or inventory write-offs;
- Manufacturing shutdown;
- Contract termination;
- Litigation and legal review;
- Collaboration wind-down.
Portfolio effects
The withdrawal weakened confidence in Biogen’s ability to expand beyond established MS products through incremental biologic launches. It also reduced the value of anti-CD25 development expertise and limited the strategic usefulness of daclizumab-related manufacturing assets.
What generic or biosimilar launch risks existed?
Before withdrawal, the main competitive risk came from established MS drugs rather than near-term biosimilar entry. After withdrawal, commercial biosimilar risk effectively fell to zero because the reference product was no longer sold.
A hypothetical biosimilar program would have faced several barriers:
- Small and declining addressable market;
- Severe safety history;
- Lack of active commercial demand;
- Need for comparative analytical and clinical evidence;
- Physician reluctance to adopt a withdrawn reference molecule;
- Regulatory and pharmacovigilance complexity;
- Limited reimbursement justification.
Manufacturing barriers also mattered. Daclizumab required mammalian-cell production, antibody purification, viral clearance, formulation control, and comparability testing. Those technical requirements would have added cost without a viable market opportunity.
How strong was the daclizumab patent estate?
The patent estate was historically relevant but commercially weak at the point of withdrawal.
| Patent-estate factor |
Assessment |
| Original antibody protection |
Aged by the MS launch |
| Later use patents |
Potentially relevant before withdrawal |
| Formulation patents |
Could protect specific presentations or stability profiles |
| Manufacturing patents |
Could raise development barriers |
| Regulatory exclusivity |
No longer commercially decisive after withdrawal |
| Litigation leverage |
Low after market exit |
| Biosimilar deterrence |
Low because the product had no active market |
Patent strength must be assessed against commercial enforceability. A patent can remain legally valid while having little economic value if the product is withdrawn, the indication is unattractive, or physicians have moved to alternatives.
What is the current commercial status of daclizumab?
Daclizumab has no active branded MS business. Zinbryta is withdrawn in the United States and Europe, and its multiple sclerosis franchise has no meaningful current revenue trajectory.
The remaining commercial relevance is historical:
- It is an example of a biologic launch constrained by safety monitoring.
- It illustrates the risk of expanding an antibody into a chronic-use population.
- It demonstrates that strong biologic differentiation cannot offset severe postmarketing safety signals.
- It shows that withdrawal can terminate practical exclusivity before patent expiry becomes important.
Key Takeaways
- Daclizumab was commercialized for multiple sclerosis as Zinbryta by Biogen and AbbVie.
- U.S. revenue increased from approximately $21 million in 2016 to $46 million in 2017.
- The product was withdrawn globally in 2018 after severe liver injury and inflammatory neurological events.
- The market failure was regulatory and safety-driven, not caused by generic or biosimilar competition.
- Daclizumab was regulated as a biologic, making Purple Book and 351(k) analysis more relevant than Orange Book and Paragraph IV analysis.
- Patent rights had limited practical value after withdrawal.
- No active biosimilar market or meaningful generic-entry risk remains.
- Financial exposure was modest at the product level but included manufacturing shutdown, pharmacovigilance, regulatory, and collaboration wind-down costs.
FAQs About Daclizumab Market and Patent Status
Is daclizumab still available for multiple sclerosis?
No. Zinbryta was withdrawn from the U.S. and European markets in 2018 because of serious liver and neurological safety risks.
What were peak daclizumab sales?
Reported U.S. Zinbryta revenue reached approximately $46 million in 2017, its first full commercial year.
Was daclizumab a small-molecule drug or a biologic?
Daclizumab was a humanized monoclonal antibody and therefore a biologic product.
Could a biosimilar daclizumab still launch?
A biosimilar could theoretically be developed under the 351(k) pathway, but the withdrawn reference product and lack of commercial demand make a viable launch unlikely.
What replaced daclizumab in the multiple sclerosis market?
Patients shifted to established disease-modifying therapies, including oral agents, interferons, injectable products, and higher-efficacy monoclonal antibodies such as natalizumab and ocrelizumab, depending on clinical circumstances.
References
-
AbbVie Inc. (2018). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2017.
-
Biogen Inc. (2017). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2016.
-
Biogen Inc. (2018). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2017.
-
European Medicines Agency. (2018). Zinbryta: Withdrawal of the marketing authorisation.
-
U.S. Food and Drug Administration. (1997). FDA approves Zenapax to prevent organ rejection in kidney transplant patients.
-
U.S. Food and Drug Administration. (2016). FDA approves new drug to treat multiple sclerosis.
-
U.S. Food and Drug Administration. (2018). FDA accepts voluntary withdrawal of Zinbryta from the U.S. market.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
